Literature DB >> 19291411

The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.

J P Mitchell1, M W Nagel, V Avvakoumova, H MacKay, R Ali.   

Abstract

The abbreviated impactor measurement (AIM) concept is a potential solution to the labor-intensive full-resolution cascade impactor (CI) methodology for inhaler aerosol aerodynamic particle size measurement. In this validation study, the effect of increasing the internal dead volume on determined mass fractions relating to aerodynamic particle size was explored with two abbreviated impactors both based on the Andersen nonviable cascade impactor (ACI) operating principle (Copley fast screening Andersen impactor [C-FSA] and Trudell fast screening Andersen impactor [T-FSA]). A pressurized metered dose inhaler-delivered aerosol producing liquid ethanol droplets after propellant evaporation was chosen to characterize these systems. Measures of extrafine, fine, and coarse particle mass fractions from the abbreviated systems were compared with corresponding data obtained by a full-resolution ACI. The use of liquid ethanol-sensitive filter paper provided insight by rendering locations visible where partly evaporated droplets were still present when the "droplet-producing" aerosol was sampled. Extrafine particle fractions based on impactor-sized mass were near equivalent in the range 48.6% to 54%, comparing either abbreviated system with the benchmark ACI-measured data. The fine particle fraction of the impactor-sized mass determined by the T-FSA (94.4 +/- 1.7%) was greater than using the C-FSA (90.5 +/- 1.4%) and almost identical with the ACI-measured value (95.3 +/- 0.4%). The improved agreement between T-FSA and ACI is likely the result of increasing the dead space between the entry to the induction port and the uppermost impaction stage, compared with that for the C-FSA. This dead space is needed to provide comparable conditions for ethanol evaporation in the uppermost parts of these impactors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19291411      PMCID: PMC2663691          DOI: 10.1208/s12249-009-9201-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  9 in total

1.  Comparison of the TSI Model 3306 Impactor Inlet with the Andersen Cascade Impactor: solution metered dose inhalers.

Authors:  Paul B Myrdal; Stephen W Stein; Erik Mogalian; William Hoye; Abhishek Gupta
Journal:  Drug Dev Ind Pharm       Date:  2004-09       Impact factor: 3.225

2.  Revised internal volumes of cascade impactors for those provided by mitchell and nagel.

Authors:  M Copley; M Smurthwaite; D L Roberts; J P Mitchell
Journal:  J Aerosol Med       Date:  2005

3.  Application of heated inlet extensions to the TSI 3306/3321 system: comparison with the Andersen cascade impactor and next generation impactor.

Authors:  Paul B Myrdal; Erik Mogalian; Jolyon Mitchell; Mark Nagel; Charlie Wright; Brent Kiser; Mark Prell; Mike Woessner; Stephen W Stein
Journal:  J Aerosol Med       Date:  2006

4.  Aiming for a moving target: challenges with impactor measurements of MDI aerosols.

Authors:  Stephen W Stein
Journal:  Int J Pharm       Date:  2007-12-04       Impact factor: 5.875

5.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

6.  Effect of drug load and plate coating on the particle size distribution of a commercial albuterol metered dose inhaler (MDI) determined using the Andersen and Marple-Miller cascade impactors.

Authors:  M M Nasr; D L Ross; N C Miller
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

7.  Novel system to investigate the effects of inhaled volume and rates of rise in simulated inspiratory air flow on fine particle output from a dry powder inhaler.

Authors:  Varsha Chavan; Richard Dalby
Journal:  AAPS PharmSci       Date:  2002

8.  A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions.

Authors:  Stephen W Stein; Paul B Myrdal
Journal:  J Pharm Sci       Date:  2004-08       Impact factor: 3.534

9.  Balancing ethanol cosolvent concentration with product performance in 134a-based pressurized metered dose inhalers.

Authors:  Abhishek Gupta; Stephen W Stein; Paul B Myrdal
Journal:  J Aerosol Med       Date:  2003
  9 in total
  5 in total

1.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-05-18       Impact factor: 3.246

2.  Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of metered dose inhalers (MDI).

Authors:  Changning Guo; Diem Ngo; Shafiq Ahadi; William H Doub
Journal:  AAPS PharmSciTech       Date:  2013-06-19       Impact factor: 3.246

3.  Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).

Authors:  Terrence P Tougas; David Christopher; Jolyon P Mitchell; Helen Strickland; Bruce Wyka; Mike Van Oort; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

4.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

5.  The effect of nonideal cascade impactor stage collection efficiency curves on the interpretation of the size of inhaler-generated aerosols.

Authors:  D L Roberts; J P Mitchell
Journal:  AAPS PharmSciTech       Date:  2013-03-19       Impact factor: 3.246

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.